140
Participants
Start Date
June 21, 2022
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Placebo
Administration of Placebo
ACI-24.060 at Dose A
Administration of Dose A of ACI-24.060
ACI-24.060 at Dose B
Administration of Dose B of ACI-24.060
ACI-24.060 at Dose C
Administration of Dose C of ACI-24.060
ACI-24.060 at Dose D
Administration of Dose D of ACI-24.060
Placebo
Administration of Placebo
ACI-24.060 at Dose X
Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
ACI-24.060 at Dose Y
Administration of Dose Y of ACI-24.060
RECRUITING
Indiana University / IU Health, Indianapolis
RECRUITING
The Washington University, St Louis
RECRUITING
UT Health San Antonio, San Antonio
RECRUITING
Barrow Neurological Institute, Phoenix
RECRUITING
University of Kansas Medical Center Research Institute, Fairway
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona
RECRUITING
Hospital de la Santa Creu i Sant Pau, Barcelona
WITHDRAWN
Hospital Universitario Virgen De Las Nieves, Granada
RECRUITING
Hospital Clínico San Carlos, Madrid
RECRUITING
Hospital Universitario de la Princesa, Madrid
RECRUITING
Hospital Universitario Marqués de Valdecilla, Santander
RECRUITING
Hospital Universitario y Politécnico La Fe, Valencia
RECRUITING
Cambridge and Peterborough NHS Foundation Trust - Windsor Research Units, Cambridge
RECRUITING
Liverpool University Hospitals NHS Foundation Trust, Liverpool
RECRUITING
Re:Cognition Health Limited, London
RECRUITING
South London and Maudsley NHS Foundation Trust of The Maudsley Hospital, London
RECRUITING
Oxford Health NHS Foundation Trust, Oxford
Lead Sponsor
Collaborators (1)
Worldwide Clinical Trials
OTHER
AC Immune SA
INDUSTRY